ALGENSCRIBE
Business purpose.
Le développement de tous produits et technologies utilisant des modules d'édition du génome nucléaire et mitochondrial ainsi que des systèmes de vectorisation et/ou délivrance dans les domaines des outils de recherche en biotechnologie, de la bioproduction, de la thérapie de pathologies humaines, du diagnostic de pathologies humaines et des thérapies et diagnostics vétérinaires.
Identity
- Legal form
- SAS, simplified joint-stock company
- Activity
- Research and experimental development on biotechnology (72.11Z)
- Sector
- Scientific research and development
- Headcount
- 1 to 2 employees
- Created
- 21 Dec 2022
- Share capital
- 37,648.00 EUR
- Registered with the trade register
- 30 Dec 2022
- Financial year end
- 31/12
- Establishments
- 1
Directors
- FREDERIC GILLES ZAMPATTI 56 years old, 02/1970 President de SAS
Other companies at the same address
23 other company head offices are registered at this address.
Establishments
Financial strength
Financial score
68 / 100 B
Confidence: low · computed on the financial year ended 31 Dec 2024
- Equity to assets (54.2 %)
- 19.6 out of 30
- EBITDA margin
- data missing, component not taken into account
- Liquidity (591.5 %)
- 16.4 out of 20
- Debt (69.0 %)
- 8.5 out of 15
- Revenue trend
- data missing, component not taken into account
formula fin-1.0
Legal score
88 / 100 A
Confidence: high
- No insolvency proceedings
- 40.0 out of 40
- Currently trading
- 20.0 out of 20
- Age (3.9 years)
- 7.8 out of 20
- Accounts filed recently
- 20.0 out of 20
formula leg-1.0
These scores are computed by us from public data, using a published formula. They are not advice, not a guarantee, not a credit decision, and they do not replace a review of the accounts. See how it is calculated
Revenue and earnings
Detailed accounts for this company are not reproduced here, but its main aggregates are public.
| Financial year | Revenue | Change | EBITDA | Net income |
|---|---|---|---|---|
| 31 Dec 2024 | 0 € | first year on record | 0 € | -119,204 € |
Aggregates published by the French Directorate General for Enterprise, computed from accounts filed with the commercial court.
Explore similar companies
Collective agreements
Agreements declared by the employer in its payroll filings.
-
Convention collective nationale de l'industrie pharmaceutique du 6 avril 1956. Etendue par arrêté du 15 novembre 1956 JORF 14 décembre 1956.
IDCC 0176 · repealed · 1 establishment · declared in August 2026
Legal notices
-
Filing of accounts 7 May 2026
- Court :
- Greffe du Tribunal de Commerce de nice
- Type of filing :
- Comptes annuels et rapports
- Closing date :
- 31/12/2025
BODACC C n 20260087, annonce n 277 · Proof of publication (PDF)
-
Amendment 23 Nov 2025
- Court :
- Greffe du Tribunal de Commerce de Nice
- Amendment :
- Modification survenue sur le capital.
BODACC B n 20250225, annonce n 160 · Proof of publication (PDF)
-
Amendment 3 Aug 2025
- Court :
- Greffe du Tribunal de Commerce de Nice
- Amendment :
- Modification survenue sur le capital.
BODACC B n 20250147, annonce n 146 · Proof of publication (PDF)
-
Filing of accounts 1 Aug 2025
- Court :
- Greffe du Tribunal de Commerce de nice
- Type of filing :
- Comptes annuels et rapports
- Closing date :
- 31/12/2024
BODACC C n 20250146, annonce n 473 · Proof of publication (PDF)
-
Amendment 6 Feb 2025
- Court :
- Greffe du Tribunal de Commerce de Nice
- Amendment :
- Modification survenue sur le capital.
BODACC B n 20250026, annonce n 219 · Proof of publication (PDF)
-
Filing of accounts 23 Jan 2025
- Court :
- Greffe du Tribunal de Commerce de nice
- Type of filing :
- Comptes annuels et rapports
- Closing date :
- 31/12/2023
BODACC C n 20250016, annonce n 628 · Proof of publication (PDF)
-
Amendment 5 Jul 2023
- Court :
- Greffe du Tribunal de Commerce de Nice
- Amendment :
- Modification survenue sur le capital.
BODACC B n 20230128, annonce n 68 · Proof of publication (PDF)
Filings and accounts
- Formality 20 Nov 2025
- Formality 30 Jul 2025
- Formality 4 Feb 2025
Change history
- officer_appointed (empty) → President de SAS 9 Oct 2026
- capital 30327.00 → 25581.00 3 Oct 2026
- capital 28614.00 → 30327.00 2 Oct 2026
- capital 37648.00 → 28614.00 2 Oct 2026
- registered_address (empty) → Ceei Nice Côte D'Azur 06200 Nice 1 Oct 2026
- capital (empty) → 37648.00 1 Oct 2026
Frequently asked questions about ALGENSCRIBE
- What is the SIREN number of ALGENSCRIBE?
- The SIREN number of ALGENSCRIBE is 922650718. Its intra-community VAT number is FR33922650718.
- Where is the head office of ALGENSCRIBE?
- Head office address: 61 AVENUE SIMONE VEIL, 06200 NICE.
- When was ALGENSCRIBE founded?
- ALGENSCRIBE was founded on 21 Dec 2022.
- What does ALGENSCRIBE do?
- Its declared main activity is: Research and experimental development on biotechnology (NAF code 72.11Z).
- Who runs ALGENSCRIBE?
- The officer listed in the register is FREDERIC GILLES ZAMPATTI (President de SAS).
- What is the revenue of ALGENSCRIBE?
- The latest published revenue is 0 €, for the 2024 financial year.
- How many employees does ALGENSCRIBE have?
- The declared headcount is 1 to 2 employees. Insee data for 2024.
- Is ALGENSCRIBE subject to insolvency proceedings?
- No ongoing insolvency proceedings are published in the BODACC for this company.